{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T12:18:37Z","timestamp":1779106717627,"version":"3.51.4"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,18]]},"DOI":"10.7759\/cureus.109095","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T11:59:56Z","timestamp":1779105596000},"source":"Crossref","is-referenced-by-count":0,"title":["Gastroesophageal Junction Adenocarcinoma Presenting With De Novo Metastatic Disease and Ovarian Metastasis in a Young Woman With Atypical Chest Pain"],"prefix":"10.7759","author":[{"given":"Yanina","family":"Nikolaus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafah","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2016.01.013","article-title":"The epidemic of oesophageal carcinoma: where are we now?","volume":"41","author":"Thrift AP","year":"2016","unstructured":"Thrift AP. The epidemic of oesophageal carcinoma: where are we now?. Cancer Epidemiol. 2016, 41:88-95. 10.1016\/j.canep.2016.01.013","journal-title":"Cancer Epidemiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2017.155","article-title":"Predicting the future burden of esophageal cancer by histological subtype: international trends in incidence up to 2030","volume":"112","author":"Arnold M","year":"2017","unstructured":"Arnold M, Laversanne M, Brown LM, Devesa SS, Bray F. Predicting the future burden of esophageal cancer by histological subtype: international trends in incidence up to 2030. Am J Gastroenterol. 2017, 112:1247-55. 10.1038\/ajg.2017.155","journal-title":"Am J Gastroenterol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.08.002","article-title":"Early-onset esophageal adenocarcinoma presents with advanced-stage disease but has improved survival compared with older individuals","volume":"159","author":"Kolb JM","year":"2020","unstructured":"Kolb JM, Han S, Scott FI, Murphy CC, Hosokawa P, Wani S. Early-onset esophageal adenocarcinoma presents with advanced-stage disease but has improved survival compared with older individuals. Gastroenterology. 2020, 159:2238-40.e4. 10.1053\/j.gastro.2020.08.002","journal-title":"Gastroenterology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/01.pap.0000213038.85704.e4","article-title":"From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary: part I. Historical perspective, general principles, mucinous tumors including the Krukenberg tumor","volume":"13","author":"Young RH","year":"2006","unstructured":"Young RH. From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary: part I. Historical perspective, general principles, mucinous tumors including the Krukenberg tumor. Adv Anat Pathol. 2006, 13:205-27. 10.1097\/01.pap.0000213038.85704.e4","journal-title":"Adv Anat Pathol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.5858\/2006-130-1725-AILAKT","article-title":"An in-depth look at Krukenberg tumor: an overview","volume":"130","author":"Al-Agha OM","year":"2006","unstructured":"Al-Agha OM, Nicastri AD. An in-depth look at Krukenberg tumor: an overview. Arch Pathol Lab Med. 2006, 130:1725-30. 10.5858\/2006-130-1725-AILAKT","journal-title":"Arch Pathol Lab Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0019","article-title":"Esophageal and esophagogastric junction cancers, version 2.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Ajani JA","year":"2023","unstructured":"Ajani JA, D'Amico TA, Bentrem DJ, et al.. Esophageal and esophagogastric junction cancers, version 2.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023, 21:393-422. 10.6004\/jnccn.2023.0019","journal-title":"J Natl Compr Canc Netw"},{"key":"ref8","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken MM","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982, 5:649-55.","journal-title":"Am J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian YY","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al.. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021, 398:27-40. 10.1016\/S0140-6736(21)00797-2","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun JM","year":"2021","unstructured":"Sun JM, Shen L, Shah MA, et al.. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021, 398:759-71. 10.1016\/S0140-6736(21)01234-4","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial","volume":"6","author":"Shitara K","year":"2020","unstructured":"Shitara K, Van Cutsem E, Bang YJ, et al.. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 2020, 6:1571-80. 10.1001\/jamaoncol.2020.3370","journal-title":"JAMA Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/495061-gastroesophageal-junction-adenocarcinoma-presenting-with-de-novo-metastatic-disease-and-ovarian-metastasis-in-a-young-woman-with-atypical-chest-pain","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T11:59:57Z","timestamp":1779105597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/495061-gastroesophageal-junction-adenocarcinoma-presenting-with-de-novo-metastatic-disease-and-ovarian-metastasis-in-a-young-woman-with-atypical-chest-pain"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.109095","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,18]]}}}